The total number of records retrieved from this search are 28. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_360	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_364	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_368	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration0.1 MOI	In-vitro result98% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_372	Virus nameHerpes simplex virus	Virus strainSeprehvir (HSV1716)	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationΔγ134.5 attenuated virus mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC or from the Pediatric Preclinical Testing Program (PPTP)	Origin of cell lineHuman neuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTS cell survival assay	In-vitro virus concentration1 MOI	In-vitro result72% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26583803
IDOV_939	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result90% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_940	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result80% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_941	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result70% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_942	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro result70% cancer cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_971	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 virus particle/cell	In-vitro result70% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_972	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 virus particle/ cell	In-vitro result70% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_973	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 virus particle/ cell	In-vitro result70% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_974	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineAlabama-Birmingham	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 virus particle/ cell	In-vitro result70% cancer cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1039	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result100% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1040	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result100% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1041	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result100% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1042	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result90% cell survival after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1043	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result80% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1044	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result80% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1045	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result80% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1046	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result20% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1047	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result90% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1048	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result60% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1049	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result20% cell survival after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1050	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell killing after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1051	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10 pfu/cell	In-vitro result10% cell survival after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1052	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration100 pfu/cell	In-vitro result10% cell survival after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1053	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1000 pfu/cell	In-vitro result10% cell survival after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577
IDOV_1054	Virus nameHerpes simplex virus	Virus strainHSV-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant NV1066	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineMediGene Inc. San Diego, CA	Origin of cell lineNeuroblastoma cell line	Cell lineCHLA-20	Concentration of cell line4.0E+3 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration10000 pfu/cell	In-vitro result100% cell killing after 8 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15570577